Immix Biopharma (IMMX) Non Operating Income (2021 - 2026)

Immix Biopharma has disclosed Non Operating Income across 6 years of filings, most recently posting $717168.0 for Q1 2026.

• Non Operating Income for Q1 2026 came in at $717168.0, up 377.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (up 24.77% YoY), and the FY2025 annual result was $555526.0, down 45.4% from the prior year.
• Non Operating Income came in at $717168.0 for Q1 2026 at Immix Biopharma, up from $216712.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $717168.0 in Q1 2026 to a low of -$388.0 in Q1 2022.
• The 5-year median for Non Operating Income is $168035.0 (2024), against an average of $179767.6.
• Across the five-year window, Non Operating Income plunged 98.3% in 2022 and soared 118309.17% in 2023, its largest moves.
• Immix Biopharma's Non Operating Income stood at $14725.0 in 2022, then soared by 1452.29% to $228575.0 in 2023, then fell by 18.69% to $185851.0 in 2024, then increased by 16.61% to $216712.0 in 2025, then surged by 230.93% to $717168.0 in 2026.
• The last three Non Operating Income figures came in at $717168.0 (Q1 2026), $216712.0 (Q4 2025), and $84539.0 (Q3 2025), per Business Quant data.